Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
arcticnovartis
- New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presented
- Long-term Cosentyx® data build on extensive body of evidence supporting continuous use in hidradenitis suppurativa (HS) and psoriasis
- Additional Cosentyx data in HS include indirect comparison of efficacy and safety vs bimekizumab